Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular ImmunotherapyInitial applications to focus on the treatment of solid tumor malignancies Clinical trials expected to begin in 2019 PHILADELPHIA, June 27, 2018-- Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately-held biotechnology company focused on the development of macrophage-based immunotherapeutics, today announced the close of a $53 million Series A financing to further expand its technology platform and rapidly drive its programs toward clinical development. The financing was led by AbbVie Ventures and HealthCap and includes existing seed investors IP Group, Penn Medicine and Grazia Equity.